At a glance
ClinicalIndex Comparison RecordN/ACompleted· 24,500 enrolled
Drug / intervention
Empagliflozin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists Cost of Care Study: a German Claims Data Analysis
In Brief
An observational study evaluating Empagliflozin, DPP-4i, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 24,500 participants across 1 site.
Detailed Summary
Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedMar 2020
Enrollment StartNov 2020
Primary CompletionSep 2021
TodayJul 2026
First PostedMar 4, 2020
Enrollment StartNov 16, 2020
Primary CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.3 years ago
Interventions
Empagliflozindrug
film coated tablet
DPP-4idrug
film coated tablets, specifically Sitagliptin
GLP-1-RAdrug
subcutaneous injection or tablet